CONCLUSIONS

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb.

Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet].

Show details

Contents

< Prev Next >

5CONCLUSIONS

The cost per course of treatment with ingenol mebutate ($383) is similar to that of imiquimod 5% depending on how it is dosed ($353 to $529),² but considerably higher than that of 5-FU ($34). Whether ingenol mebutate will generate savings or incur additional costs if listed by public plans depends on how ingenol mebutate will be utilized. If ingenol mebutate is used only by AK patients who have failed 5-FU treatment, listing ingenol mebutate may generate modest savings when compared with imiquimod 5%. However, if ingenol mebutate is used as a first-line therapy for AK (as per the Health Canada indication), listing ingenol mebutate would result in substantially higher costs being incurred by public plans.

Footnotes

2: These costs are based on a range of 12 weeks to 16 weeks treatment with imiquimod 5%. The low range of 12 weeks was provided by clinical expert advice where patients receive one 24-dose pack of imiquimod 5%, while the upper range is based on patients receiving a pack of 24 doses and a pack of 12 doses (total 36 doses) to cover 16 weeks of treatment; based on the pack size and treatment regimen specified in the imiquimod 5% Product Monograph.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK195581

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb. 5, CONCLUSIONS.